SEC filings

Viatris (VTRS)

Recent filings Viatris made with the SEC, newest first. Most have a short AI-generated summary, and every one links to the original.

CIK 0001792044All filings on SEC.gov

AI-generated summary
  1. 10-QQuarterly report

    Quarterly report

    Viatris filed its quarterly report for the period ended September 30, 2026, covering its business, four reportable segments, strategic initiatives, and risks including uncertainty over completing its proposed acquisition of Pacira and…

  2. 8-KCurrent report

    Results of Operations and Financial Condition; Other Events

    Viatris reported third-quarter 2026 total revenues of $3.75 billion, a U.S. GAAP net loss of $325 million, and adjusted EBITDA of $1.20 billion, and raised its 2026 financial guidance midpoints for all metrics. It also announced U.S. …

  3. 8-KCurrent report

    Entry into a Material Definitive Agreement; Other Events

    Viatris agreed to acquire Pacira BioSciences for $36.50 per share in cash through a tender offer by Viatris's wholly owned subsidiary Peach Purchaser Sub Inc., to be followed by a merger in which Pacira becomes a wholly owned Viatris…

  4. 10-QQuarterly report

    Quarterly report

    Viatris filed its quarterly report on Form 10-Q for the period ended June 30, 2026, whose management discussion and analysis restates the company's business overview and the risk factors that could cause actual results to differ from its…

  5. 8-KCurrent report

    Results of Operations and Financial Condition; Other Events

    Viatris reported second-quarter 2026 total revenues of $3.8 billion, up 5% on a reported basis from a year earlier, with a U.S. GAAP net loss of $119 million and adjusted EBITDA of $1.2 billion, and raised the midpoints of its full-year…

Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.

Follow Viatris in Readster

Add Viatris to your watchlist and its SEC filings reach your brief alongside the news about it, every line cited to its source. Readster also follows topics, people, newsletters and podcasts.

No credit card. When the trial ends, you move to Readster Free unless you subscribe.